Provided by Tiger Trade Technology Pte. Ltd.

Park Hotels & Resorts Inc.

10.76
+0.15501.46%
Volume:815.36K
Turnover:8.83M
Market Cap:2.17B
PE:-7.52
High:10.92
Open:10.58
Low:10.58
Close:10.60
52wk High:12.39
52wk Low:8.27
Shares:201.40M
Float Shares:195.63M
Volume Ratio:0.45
T/O Rate:0.42%
Dividend:1.00
Dividend Rate:9.30%
EPS(TTM):-1.4300
EPS(LYR):-1.4300
ROE:-8.31%
ROA:2.12%
PB:0.69
PE(LYR):-7.52

Loading ...

CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML

GlobeNewswire
·
Oct 21, 2025

ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025

GlobeNewswire
·
Oct 20, 2025

Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia

GlobeNewswire
·
Oct 17, 2025

Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences

GlobeNewswire
·
Oct 14, 2025

CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML

GlobeNewswire
·
Oct 13, 2025

Theriva™ Biologics Announces Upcoming Presentations at Medical Meetings

GlobeNewswire
·
Oct 13, 2025

Corporate Updates: Welding Showdown! Yunnan Aluminum Green Source Conducts Human vs. Machine Competition to Test Capabilities

Deep News
·
Oct 10, 2025

Park Hotels & Resorts Is Maintained at Neutral by UBS

Dow Jones
·
Oct 07, 2025

UBS Adjusts Park Hotels & Resorts Price Target to $11 From $10, Maintains Neutral Rating

MT Newswires Live
·
Oct 06, 2025

Press Release: Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives

Dow Jones
·
Oct 06, 2025

Wells Fargo Keeps Their Hold Rating on Park Hotels & Resorts (PK)

TIPRANKS
·
Oct 03, 2025

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

GlobeNewswire
·
Oct 03, 2025

Park Hotels & Resorts Initiated at Neutral by Cantor Fitzgerald

Dow Jones
·
Oct 01, 2025

Cantor Fitzgerald Initiates Coverage on Park Hotels & Resorts With Neutral Rating, $12 Price Target

MT Newswires Live
·
Oct 01, 2025

Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination

GlobeNewswire
·
Oct 01, 2025

Larimar Therapeutics Stock Falls After Patients Report Allergic Reaction In Pivotal Study

Benzinga_recent_news
·
Sep 29, 2025

Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia

GlobeNewswire
·
Sep 29, 2025